Vulva Cancer

The EORTC vulva cancer module is developed as a disease and treatment specific questionnaire module for vulva cancer patients to supplement the EORTC QLQ-C30. The aim of the study is to test the scale structure, reliability, and validity of the EORTC VU34 in patients diagnosed with vulva cancer at different stages of disease and with different treatment modalities.We aim to develop a questionnaire module that will allow broad international cross-cultural and cross-country adaptation which can be used in clinical trials.

The first three phases of development and validation are completed. The questionnaire is now undergoing formal field testing with psychometric analyses.

We are currently recruiting for Phase 4.

A publication on phase 3 has been drafted as is currently being reviewed by collaborators and the EORTC QLG Executive Committee.  Expected to be submitted to EJCancer.

We expect fast recruitment of the last 80 patients needed for Phase 4, as new collaborators from Jordan, Israel and Germany have started recruitment and existing collaborators can also recruit if required.

The EORTC vulva cancer module is a questionnaire developed in collaboration with patients with cancer in their outer genitals (vulva cancer). To make sure the questionnaire works as intended we need to test it in women from different countries and cultures, with different disease stages and who have undergone different treatments. This will allow us to use the questionnaire in the clinic and in future studies.